- Home
- SOS vs MYNZ Comparison
SOS vs MYNZ Comparison
Compare SOS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOS | MYNZ |
|---|---|---|
| Founded | 2004 | 2021 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 10.2M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOS | MYNZ |
|---|---|---|
| Price | $1.30 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 16.6K | ★ 385.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.56 |
| 52 Week High | $8.92 | $5.69 |
Technical Indicators
Market Signals| Indicator | SOS | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 36.49 | 25.41 |
| Support Level | $1.17 | $0.56 |
| Resistance Level | $1.39 | $1.37 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 11.70 | 7.54 |
Price Performance
Historical ComparisonAbout SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.